These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11286309)

  • 41. Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.
    Kalus JS; Moser LR
    Ann Pharmacother; 2005 Mar; 39(3):481-91. PubMed ID: 15701782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
    Dunn CJ; Jarvis B
    Drugs; 2000 Jul; 60(1):203-37. PubMed ID: 10929935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
    Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
    Brouwer MA; van den Bergh PJ; Aengevaeren WR; Veen G; Luijten HE; Hertzberger DP; van Boven AJ; Vromans RP; Uijen GJ; Verheugt FW
    Circulation; 2002 Aug; 106(6):659-65. PubMed ID: 12163424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction.
    Rubboli A
    Curr Cardiol Rev; 2008 Feb; 4(1):63-71. PubMed ID: 19924279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
    Bijsterveld NR; Moons AH; Meijers JC; Tijssen JG; Büller HR; Levi M; Peters RJ
    J Am Coll Cardiol; 2002 Mar; 39(5):811-7. PubMed ID: 11869846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of enoxaparin and dalteparin with unfractionated heparin in the treatment of non-ST elevated acute coronary syndrome.
    Ahmed M; Tariq M; Noor L; Din SU; Hafizullah M
    J Ayub Med Coll Abbottabad; 2011; 23(3):60-3. PubMed ID: 23272437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy.
    Johanson P; Wallentin L; Nilsson T; Bergstrand L; Lindahl B; Dellborg M
    Am Heart J; 2004 May; 147(5):853-8. PubMed ID: 15131542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
    Magee KD; Sevcik W; Moher D; Rowe BH
    Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
    Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
    Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy--a randomised controlled trial.
    McMahon GS; Webster SE; Hayes PD; Jones CI; Goodall AH; Naylor AR
    Eur J Vasc Endovasc Surg; 2009 Jun; 37(6):633-9. PubMed ID: 19328023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of anticoagulants in ST-segment elevation myocardial infarction patients; a focus on low-molecular-weight heparin.
    Gurm HS; Eagle KA
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):59-69. PubMed ID: 18165932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.